Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects having previously been immunized with two 0.25 mL doses of Pandemrix, given at least 21 days apart, at the age of 6 months to 9 years inclusive at the time of first vaccination.~* Subjects having received the last dose of Pandemrix at least six months prior to study enrolment.~* Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) \[LAR(s)\] can and will comply with the requirements of the protocol.~* Written informed consent obtained from the parent(s)/LAR(s) of the subjects.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Parent/LAR with access to a consistent means of telephone contact, land line or mobile, but NOT a pay phone or other multiple-user device.~Exclusion Criteria:~* Active participation in other clinical trials.~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of the study vaccine or planned use during the study period.~* Planned administration of any vaccine 30 days prior and 30 days after any study vaccine administration.~* Chronic administration of immunosuppressants or other immune-modifying drugs within three months prior to enrolment in this study or planned administration during the study period.~* Acute disease and/or fever at the time of enrolment.~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.~* Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and physical examination.~* Administration of immunoglobulins and/or any blood products within the three months prior to the enrolment in this study, or planned use during the study.~* Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine.~* History of seizures or progressive neurological disease.~* Subjects having received an H1N1v pandemic vaccine other than Pandemrix or having received the 2010/2011 seasonal influenza vaccine.~* Child in care.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- Fluarix 6-11 months Group (Type: EXPERIMENTAL): Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
- Fluarix 12-35 months Group (Type: EXPERIMENTAL): Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
- Fluarix 3-9 years Group (Type: EXPERIMENTAL): Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
- Havrix Junior 6-11 months Group (Type: ACTIVE_COMPARATOR): Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
- Havrix Junior 12-35 months Group (Type: ACTIVE_COMPARATOR): Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
- Havrix Junior 3-9 years Group (Type: ACTIVE_COMPARATOR): Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete